These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36943079)

  • 1. Recurrence Patterns and Patient Outcomes in Resected Lung Adenocarcinoma Differ according to Ground-Glass Opacity at CT.
    Park S; Lee SM; Choe J; Choi S; Do KH; Seo JB
    Radiology; 2023 May; 307(3):e222422. PubMed ID: 36943079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the prognostic implication of ground-glass opacity on CT according to pathological nodal status in lung cancers treated with lobectomy or pneumonectomy.
    Park S; Lee SM; Choe J; Choi S; Kim S; Do KH; Seo JB
    Eur Radiol; 2022 Jul; 32(7):4405-4413. PubMed ID: 35141781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for lymph node metastasis and surgical methods in patients with early-stage peripheral lung adenocarcinoma presenting as ground glass opacity.
    Wang Y; Jing L; Wang G
    J Cardiothorac Surg; 2020 Aug; 15(1):121. PubMed ID: 32782020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological features and prognostic implications of ground-glass opacity components on computed tomography for clinical stage I lung adenocarcinoma.
    Katsumata S; Aokage K; Ishii G; Hoshino H; Suzuki J; Miyoshi T; Tane K; Samejima J; Tsuboi M
    Surg Today; 2021 Jul; 51(7):1188-1202. PubMed ID: 33745094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minor (≤ 10%) Ground-Glass Opacity Component in Clinical Stage I Non-Small Cell Lung Cancer: Associations With Pathologic Characteristics and Clinical Outcomes.
    Li M; Wang J; Bao X; Wang F; Zhou F; Song N; Wan Z; Li W; Zhang L
    AJR Am J Roentgenol; 2024 Aug; 223(2):e2431283. PubMed ID: 38809121
    [No Abstract]   [Full Text] [Related]  

  • 6. Resected lung adenocarcinoma with lymph node metastasis: is ground glass opacity component a prognostic factor?
    Deng C; Jiang C; Ma X; Fu F; Wang S; Li Y; Zhang Y; Chen H
    Transl Lung Cancer Res; 2024 Jul; 13(7):1609-1619. PubMed ID: 39118885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of wedge resection for pulmonary ground-glass opacity nodules.
    Cho JH; Choi YS; Kim J; Kim HK; Zo JI; Shim YM
    Ann Thorac Surg; 2015 Jan; 99(1):218-22. PubMed ID: 25440277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller.
    Zhang C; He Z; Cheng J; Cao J; Hu J
    Clin Lung Cancer; 2021 Mar; 22(2):e160-e168. PubMed ID: 33160898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?
    Nakamura S; Fukui T; Kawaguchi K; Fukumoto K; Hirakawa A; Yokoi K
    Lung Cancer; 2015 Jul; 89(1):38-42. PubMed ID: 25963638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of lymphovascular invasion for stage I lung adenocarcinoma based on the presence of ground-glass opacity.
    Choe J; Lee SM; Park S; Choi S; Do KH; Seo JB
    Eur Radiol; 2024 Sep; ():. PubMed ID: 39285027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma.
    Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
    J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma.
    Higashi K; Sakuma T; Ito K; Niho S; Ueda Y; Kobayashi T; Sekiguchi R; Takahashi T; Kato T; Tonami H
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):373-81. PubMed ID: 18931837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of Ground-Glass Opacity Components in 5-Year Survivors With Resected Lung Adenocarcinoma.
    Shigefuku S; Shimada Y; Hagiwara M; Kakihana M; Kajiwara N; Ohira T; Ikeda N
    Ann Surg Oncol; 2021 Jan; 28(1):148-156. PubMed ID: 32920721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of CT-defined ground-glass opacity in early-stage lung adenocarcinomas: a single-center study and meta-analysis.
    Lee JH; Choi Y; Hong H; Kim YT; Goo JM; Kim H
    Eur Radiol; 2024 Mar; 34(3):1905-1920. PubMed ID: 37650971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective definition and measurement method of ground-glass opacity for planning limited resection in patients with clinical stage IA adenocarcinoma of the lung.
    Matsuguma H; Nakahara R; Anraku M; Kondo T; Tsuura Y; Kamiyama Y; Mori K; Yokoi K
    Eur J Cardiothorac Surg; 2004 Jun; 25(6):1102-6. PubMed ID: 15145016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid component ratio influences prognosis of GGO-featured IA stage invasive lung adenocarcinoma.
    Sun F; Huang Y; Yang X; Zhan C; Xi J; Lin Z; Shi Y; Jiang W; Wang Q
    Cancer Imaging; 2020 Dec; 20(1):87. PubMed ID: 33308323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival.
    Berry MF; Gao R; Kunder CA; Backhus L; Khuong A; Kadoch M; Leung A; Shrager J
    Clin Lung Cancer; 2018 Jan; 19(1):e47-e51. PubMed ID: 28743420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions.
    Asamura H; Suzuki K; Watanabe S; Matsuno Y; Maeshima A; Tsuchiya R
    Ann Thorac Surg; 2003 Oct; 76(4):1016-22. PubMed ID: 14529977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma.
    Miyoshi T; Aokage K; Katsumata S; Tane K; Ishii G; Tsuboi M
    Ann Thorac Surg; 2019 Jul; 108(1):249-255. PubMed ID: 30876742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.